Annual Report 2021 - Bristol Myers Squibb
The touch that transforms
We believe that success of our science is measured by the lives we touch. So we are always working—pushing the boundaries of what's possible to transform lives today and tomorrow.
Giovanni Caforio
Board Chair, Chief Executive Officer
Our patients
“I have to pinch myself because I can’t believe where I am today and that this is my life.”
A Single Touch Can Transform Patients’ Lives
Our scientists are accelerating transformational science in areas of high unmet need, bringing hope to more patients.
“Lupus is a long-term fight. You’ll have to work at it every single day. But it doesn’t take anything away from who you are individually. It takes nothing away from your power.”
Our Science
Looking back on a rich history and ahead toward a robust pipeline
How CAR T cell therapies are helping patients in need
We believe in the power of science to address the greatest healthcare challenges of our time. Today, that power is increasingly enabled and amplified by computer science and digital capabilities like artificial intelligence (AI) and machine learning.
A decade after a landmark approval, our research continues to uncover breakthroughs in immune checkpoint inhibition
Our Community
The touch that transforms the communities we serve
We believe in the power of science to address the greatest healthcare challenges of our time. Today, that power is increasingly enabled and amplified by computer science and digital capabilities like artificial intelligence (AI) and machine learning.
At Bristol Myers Squibb, valuing diverse perspectives is deliberate, and strengthening a culture of inclusion is intentional. Our global People & Business Resource Groups (PBRGs) are aligned to a transformational, single-leader business model that has helped to inform key business decisions and enhance our global patient focus.
We are partnering with Historically Black Colleges and Universities (HBCUs) to nurture promising young professionals among underrepresented groups.
More diverse clinical researchers and investigators can act as a bridge to underrepresented patient populations, potentially increasing their participation in clinical trials. The Foundation has an ambitious program to train hundreds of community-oriented clinicians in the next five years.
A team of BMS scientists and their collaboration partners at the Scripps Research Institute won the prestigious U.S. Environmental Protection Agency’s Green Chemistry Challenge Award for inventing a series of reagents derived from citrus peels.
Transforming patients' lives through science
The touch that transforms
2021 Annual Report
Visit bms.com to see how we're bringing a human touch to everything we do.
© 2024 Bristol-Myers Squibb Company
The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at www.bms.com.